Anti-obesity drug maker Novo Nordisk says it will invest $6bn on expanding its production facilities in the Danish town of Kalundborg.
Europe’s biggest pharmaceutical firm, it makes Wegovy, one of about nine anti-obesity drugs in a market predicted to be worth $100bn within a decade.
The company employs 61,400 people in 80 countries. Its market capitalisation currently stands at $350bn, roughly equal to Denmark’s GDP.
It set up its Kalundborg production base in 1969. Covering 160ha, it employs around 4,400 people.
The latest investment will add 17ha of production space, with projects scheduled to finish between 2025 and 2029.
The new facilities are expected to create 8,000 jobs, with 3,000 employed to build them.
Over the past 20 years or so, Novo Nordisk has invested more than $5bn in Kalundborg, most recently building four factories and rebuilding three others.